Wendell Amy McBride Acquires Shares of Axogen, Inc.

Wendell Amy McBride recently bought 4,392 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 24, 2026. This insider purchase was not part of a pre-planned trading program, indicating a direct acquisition by McBride.

Other Institutional Activity in Axogen, Inc.

Several institutional investors have also been active in Axogen, Inc. First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, leaving it with 4,002,768 shares valued at about $132.6 million, which marks a 23.5% decrease. Meanwhile, BlackRock, Inc. increased its position by 151,414 shares, now holding 3,870,851 shares worth approximately $128.2 million, a 4.1% increase. Morgan Stanley added 536,112 shares to its portfolio, ending with 3,122,982 shares valued at $103.5 million, reflecting a 20.7% increase. Vanguard Capital Management LLC opened a new position with 2,291,563 shares, valued at about $75.9 million. Arrowmark Colorado Holdings LLC grew its stake by 441,157 shares, holding 1,915,439 shares worth $63.5 million, a 29.9% increase.

Axogen, Inc. Stock Down 12.7%

Shares of Axogen, Inc. traded near $44.49 on Saturday. The company has a market cap of approximately $2.37 billion and a forward P/E ratio of about 61.1. Its beta is 1.118, indicating slightly higher volatility compared to the market. The stock's 52-week range is between $10.20 and $46.00, with a 50-day moving average of $41.31 and a 200-day moving average of $30.96. Axogen maintains a strong current ratio of 7.101 and a quick ratio of 4.994, reflecting solid short-term liquidity, with a debt-to-equity ratio of 8.432.

Recent Earnings

Axogen, Inc. reported revenue of approximately $238.1 million, with a revenue growth rate of 26.6%. However, the company posted a net margin of -13.21% and a return on equity of -17.96%, reflecting ongoing challenges in profitability. The next earnings report is scheduled for August 4, 2026.

Analysts Set New Price Targets

On April 29, 2026, Canaccord Genuity, Citizens, and Wells Fargo all maintained their 'buy' ratings for Axogen, Inc. Canaccord Genuity and Citizens set a price target of $50, while Wells Fargo's target was $48. The consensus among nine analysts is a 'buy' rating, with a mean price target of $50.78.

About Axogen, Inc.

Axogen, Inc. is a healthcare company specializing in medical devices for peripheral nerve regeneration and repair. Headquartered in Alachua, Florida, the company develops products like the Avance Nerve Graft and Axoguard Nerve Connector, which are used in surgical nerve repair. Led by CEO Ms. Lindsey Hartley, the company employs 622 people and provides its products to hospitals and surgery centers worldwide.

Bottom Line

Wendell Amy McBride's purchase of Axogen shares highlights insider interest in the company's prospects. Axogen's stock shows strong institutional backing, with several funds adjusting their positions recently. Analysts maintain a positive outlook with 'buy' ratings, despite the company's current profitability challenges. Investors should note that insider and institutional activity can provide insights but are not definitive indicators of future performance.